ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Regulatory news

EU · EU licence (European Commission)

Methylphenidate hydrochloride (Tuzulby)

Tuzulby is indicated as part of a comprehensive treatment programme for attention-deficit / hyperactivity disorder (ADHD) in children and adolescents 6-17 years old when remedial measures alone prove insufficient. Treatment must be under the supervision of a specialist in childhood behavioural disorders. Diagnosis should be made… Show the full indication

Tuzulby is indicated as part of a comprehensive treatment programme for attention-deficit / hyperactivity disorder (ADHD) in children and adolescents 6-17 years old when remedial measures alone prove insufficient. Treatment must be under the supervision of a specialist in childhood behavioural disorders. Diagnosis should be made according to Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria or the guidelines in International Classification of Diseases, Tenth Revision (ICD-10) and should be based on a complete history and evaluation of the patient. Diagnosis cannot be made solely on the presence of one or more symptoms.

CHMP opinion 12 Dec 2024 → EU licence 28 Feb 2025 · Neuraxpharm Pharmaceuticals S.L.

Research

Palliative and end-of-life care · BMJ Support Palliat Care · 2026-06-29

Meta-analysis of 9 RCTs (668 patients) with cancer-related fatigue: methylphenidate slightly reduced fatigue v placebo (SMD 0.23), with no significant increase in adverse events; trial sequential analysis found insufficient information to confirm.

Meta-analysisn = 668
Wen et al. Methylphenidate in improving cancer-related fatigue: efficacy and safety - systematic review and meta-analysis of randomised controlled trials with trial sequential analysis

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.